Sidi Chen

Sidi Chen joined the Yale Faculty in 2015 in the Department of Genetics, Systems Biology Institute, and Yale Cancer Center. His research focuses on providing a global understanding of biological systems and development of novel breakthrough therapeutics. His major vision is to develop next-generation technologies and turn them into effective and safe therapeutics. By intersecting two emerging fields, Dr. Chen innovated the concept “gene editing for, of, and as immunotherapy”. He published many high-profile original research publications in journals such as Cell, Nature, Science, Nature Biotechnology, Nature Immunology, Nature Methods, Nature Biomedical Engineering, Cell Metabolism, Cell Research. He pioneered CRISPR-mediated tumor modeling and screening, performed the first in vivo CRISPR screen, and developed MAEGI as a novel immune gene therapy concept. Dr. Chen is named as inventor/co-inventor on >30 patents or patent applications on gene editing, genetic screening, tumor modeling, cancer immunotherapy, and cell therapy. His science has formed the bases for two venture/pharma-backed biotech startups for the development of immunotherapy or cell therapies. My lab currently consists of a team of scientists, students, staffs, trainees. To date, 10 of his previous trainees hold faculty positions in various institutions.